PMR - PowerShares Dynamic Retail ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
36.28
-0.42 (-1.14%)
At close: 1:11PM EST
Stock chart is not supported by your current browser
Previous Close36.70
Open36.33
Bid0.00 x 0
Ask0.00 x 0
Day's Range36.28 - 36.33
52 Week Range32.00 - 38.29
Volume671
Avg. Volume1,964
Net Assets14.49M
NAV36.22
PE Ratio (TTM)N/A
Yield1.09%
YTD Return1.68%
Beta (3y)0.52
Expense Ratio (net)0.63%
Inception Date2005-10-26
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple

    PharmaMar (PHM) presented new preclinical data on plitidepsin showing how it regulates the viability and function of bone cells in combination with other anti-multiple myeloma drugs. In multiple myeloma, the growth of tumor cells inside the patient´s bone marrow increases the destruction of the bone, causing severe injuries.

  • PR Newswire4 days ago

    PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting

    MADRID , December 11, 2017 /PRNewswire/ -- As previously informed, the Phase III trial, ADMYRE, which compared plitidepsin in combination with dexamethasone versus dexamethasone alone met its primary endpoint, ...

  • PR Newswire4 days ago

    PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting

    MADRID , December 11, 2017 /PRNewswire/ -- As previously informed, the Phase III trial, ADMYRE, which compared plitidepsin in combination with dexamethasone versus dexamethasone alone met its primary endpoint, ...

  • 5 Retail ETFs to Buy for a Holiday-Shopping Boost
    InvestorPlace24 days ago

    5 Retail ETFs to Buy for a Holiday-Shopping Boost

    When it comes to retail stocks and exchange-traded funds (ETFs) in 2017, the tale is one of “haves and have nots.” Having exposure to, or better yet, being focused on e-commerce is a good thing; meanwhile, exposure to retailers that depend on the traditional brick-and-mortar model isn’t so great.

  • PR Newswirelast month

    Phase III Trial With Zepsyre® in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive Recommendation by IDMC

    MADRID , November 15, 2017 /PRNewswire/ -- PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III ...

  • PR Newswirelast month

    PharmaMar to Present at the Stifel 2017 Healthcare Conference

    MADRID , November 14, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present and meet institutional investors in on one meetings at the Stifel Nicolaus Weisel Healthcare Conference on November 15th in ...

  • PR Newswirelast month

    PharmaMar to Present at the Stifel 2017 Healthcare Conference

    MADRID , November 14, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present and meet institutional investors in on one meetings at the Stifel Nicolaus Weisel Healthcare Conference on November 15th in ...

  • PR Newswirelast month

    PharmaMar Presents Positive Results from a Phase II Study of lurbinectedin in Ewing's Sarcoma at the CTOS International Congress

    PharmaMar (PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing's sarcoma at the Connective Tissue Oncology Society's (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November. In abstract #2768194 entitled "Efficacy and safety of lurbinectedin (PM1183) in Ewing Sarcoma: results from a Phase 2 study" the efficacy and safety results from the Phase II basket trial were presented, in which a group of patients with this type of advanced sarcoma, that hadn´t received more than 2 prior chemotherapeutic treatment in metastatic disease, were included. At the moment of this abstract, 25 patients with Ewing's sarcoma were enrolled.

  • PR Newswirelast month

    PharmaMar Presents Positive Results from a Phase II Study of lurbinectedin in Ewing's Sarcoma at the CTOS International Congress

    PharmaMar (PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing's sarcoma at the Connective Tissue Oncology Society's (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November. In abstract #2768194 entitled "Efficacy and safety of lurbinectedin (PM1183) in Ewing Sarcoma: results from a Phase 2 study" the efficacy and safety results from the Phase II basket trial were presented, in which a group of patients with this type of advanced sarcoma, that hadn´t received more than 2 prior chemotherapeutic treatment in metastatic disease, were included. At the moment of this abstract, 25 patients with Ewing's sarcoma were enrolled.

  • PR Newswirelast month

    PharmaMar and Boryung Pharm Sign A Licensing Agreement for Zepsyre® (lurbinectedin) in Korea

    MADRID , November 7, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre® (lurbinectedin), ...

  • PR Newswirelast month

    PharmaMar Announces Partnership with 8th National Race to End Women's Cancer in Support of "End Women´s Cancer Weekend" in Washington D.C.

    PharmaMar (PHM) is pleased and honored to announce a new partnership supporting the 8th National Race to End Women's Cancer, the major awareness and fundraising event for the Foundation for Women's Cancer (FWC), which helps support research, education, and public awareness of gynecologic cancers. The Race features a 5K run and a 1-mile walk in downtown Washington, DC along historical Pennsylvania Avenue, NW, on Sunday morning, Nov. 5.

  • PR Newswire2 months ago

    The World Health Organization Selects Tivanisiran as the International Nonproprietary Name for SYL1001

    Sylentis, a Pharmaceutical Company of PharmaMar Group (PHM), pioneer in the development of new compounds based on genetic silencing technology through RNA interference (RNAi), has announced that the World Health Organization (WHO) has given its approval, as disclosed in paragraph 7 of the International Nonproprietary Name in Pharmaceutical Substances (INN) selection procedure. This entails the designation of tivanisiran as the chosen INN for the compound SYL1001.

  • PR Newswire2 months ago

    Final Data on Phase I/II in Small-cell Lung Cancer with Zepsyre® Presented at the IASCLC 18th World Conference on Lung Cancer in Japan

    PharmaMar (PHM), a biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs, has presented updated data from Zepsyre Phase I/II trials in relapse small cell lung cancer in an oral presentation at the International Association for the Study of Lung Cancer (IASLC), at 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. As Dr Calvo said, "What we have seen is an exceptional Progression Free Survival benefit, and in patients treated with PM1183 in combination with doxorubicin we saw 21 of 27 patients experience some tumor reduction.

  • PR Newswire2 months ago

    PharmaMar Will Present Final Data on PM1183 During the 18th World Lung Conference in Japan

    PharmaMar (PHM) will present the final efficacy and safety data obtained from the Phase I/II trial combining PM1183 (lurbinectedin) with doxorubicin in relapsed small-cell lung cancer during a 'Research Perspectives' oral session, on October 16th (abstract ID9249). This study shows that patients treated with PM1183 in combination with doxorubicin (Phase I/II clinical trial) reached a progression free survival (5.3 months) which compares favorably with historical data of topotecan as a single agent (the PFS varies between 3.1 and 3.5 months). The objective response rate, a 37% is observed in patients in a combination between PM1183 and doxorubicin compares to historical data of topotecan in relapsed disease of between 17% and 24%.

  • PR Newswire2 months ago

    PharmaMar Submits the Marketing Authorisation Application for Aplidin® in Switzerland

    PharmaMar (PHM) announces submission of the Marketing Authorisation Application to the Swiss Agency for Therapeutic Products (Swissmedic) for Aplidin® for the treatment of patients with multiple myeloma.

  • Retail ETFs in Focus on Early Holiday Sales Forecast
    Zacks3 months ago

    Retail ETFs in Focus on Early Holiday Sales Forecast

    Early holiday sales forecasts point to healthier sales.

  • PR Newswire3 months ago

    PharmaMar: Sylentis Presents New Data on a New Eye Drop siRNA for the Treatment of Retinal Diseases Avoiding Intraocular Injections

    MADRID , September 25, 2017 /PRNewswire/ -- This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect ...

  • PR Newswire3 months ago

    PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors

    With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar (PHM) announces the start of a Phase I clinical study with PM14, a new antitumor compound resulting from the company´s internal investigation program for the treatment of patients with advanced solid tumors. After its preclinical phase, where the compound has demonstrated its activity in solid tumors in animal models, this Phase I clinical study has the primary objective of identifying the optimal dose for the administration of PM14 in patients with advanced solid tumors.

  • PR Newswire3 months ago

    PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors

    With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar (PHM) announces the start of a Phase I clinical study with PM14, a new antitumor compound resulting from the company´s internal investigation program for the treatment of patients with advanced solid tumors. After its preclinical phase, where the compound has demonstrated its activity in solid tumors in animal models, this Phase I clinical study has the primary objective of identifying the optimal dose for the administration of PM14 in patients with advanced solid tumors.

  • Market Realist3 months ago

    A Look at Regency Centers’ Dividend Yield

    Retail REIT Regency Centers (REG) saw its revenue grow 8% in 2016, compared with 6% in 2015. The growth was driven by minimum rent, recoveries from tenants, and other income.…

  • PR Newswire3 months ago

    New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer

    The abstract #1529 'Activity of lurbinectedin (PM1183) as single agent and in combination in patients with advanced small cell lung cancer (SCLC)' shows an objective response rate of 36% when PM1183 is used as a single agent. The results become of special relevance if it is taken into account that microcitic lung cancer is the most aggressive type of lung cancer for which only one treatment exists, topotecan, approved more than 15 years ago in advanced and relapsed illness. This drug shows a response rate that varies between 17% and 24%.

  • PR Newswire3 months ago

    New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer

    The abstract #1529 'Activity of lurbinectedin (PM1183) as single agent and in combination in patients with advanced small cell lung cancer (SCLC)' shows an objective response rate of 36% when PM1183 is used as a single agent. The results become of special relevance if it is taken into account that microcitic lung cancer is the most aggressive type of lung cancer for which only one treatment exists, topotecan, approved more than 15 years ago in advanced and relapsed illness. This drug shows a response rate that varies between 17% and 24%.

  • PR Newswire3 months ago

    PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

    PharmaMar (PHM) will present the clinical data obtained from various clinical studies carried out with its antitumoral compounds of marine origin PM1183 and Yondelis®, during the European Society of Clinical Oncology (ESMO) that will be held from the 8th to the 12th of September in Madrid, Spain. The abstract #1529 titled "Activity of lurbinectedin (PM1183) as single agent and in combination in patients with advanced small cell lung cancer (SCLC)" will be presented on September 11th. In this abstract, a cohort B will be presented using a new dosing regimen as compared to cohort A that was presented at the American Society of Clinical Oncology Annual Meeting in 2015.

  • PR Newswire3 months ago

    PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

    MADRID , August 31, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present the clinical data obtained from various clinical studies carried out with its antitumoral compounds of marine origin PM1183 and ...

  • PR Newswire4 months ago

    PharmaMar Starts a Quadruple Combination Study With Aplidin® for the Treatment of Multiple Myeloma

    PharmaMar (PHM) announced the start of a multicenter quadruple combination clinical study with Aplidin® (plitidepsina), along with other compounds for the treatment of multiple myeloma. The main objective of this study is to evaluate the recommended dose (RD), the efficacy of the combination along with the safety profile, evaluating potential response and resistance markers, amongst other parameters.